RxDoctor Payments Data

Daniel Roney, MD

Family Medicine · Kansas City, MONPI 1487618690

Payments from drug & device makers

$13,216in general payments, 2019–2025

Across 793 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Pfizer$1K
  • Boehringer Ingelheim$781
  • Lilly USA, LLC$750
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$13,216100%
  • Education$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)94$1,691
AstraZeneca(2 entities)74$1,481
Novo Nordisk92$1,316
Pfizer79$1,067
Boehringer Ingelheim52$781
Lilly USA, LLC48$750
Takeda Pharmaceuticals U.S.A., Inc.25$457
GSK26$440
Amgen(2 entities)21$373
Antares Pharma, Inc.20$329
Johnson & Johnson20$298
Merck18$270
Abbott13$229
Mylan Specialty L.p.12$187
Otsuka America Pharmaceutical, Inc.8$182
Astellas Pharma US Inc9$169
Bayer10$168
Eisai Inc.9$166
Novartis9$160
Esperion Therapeutics, Inc.6$133
Corium, LLC6$120
Supernus Pharmaceuticals, Inc.6$113
Dexcom, Inc.5$106
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC7$101
Ironwood Pharmaceuticals, Inc7$101
Sumitomo Pharma America, Inc.6$93
Amarin Pharma, Inc.6$91
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$91
Tris Pharma Inc4$87
Vanda Pharmaceuticals Inc.3$86
Viatris Specialty LLC5$85
Phathom Pharmaceuticals, Inc.4$78
Biohaven Pharmaceuticals, Inc.4$77
Cranial Technologies, Inc5$75
Biohaven Pharmaceutical Holding Company Ltd.4$68
IBSA Pharma Inc.4$61
Adlon Therapeutics L.p.4$60
Teva Pharmaceuticals USA, Inc.4$57
Shire North American Group Inc4$56
Sanofi-aventis U.S. LLC3$48
Nestle Healthcare Nutrition Inc.2$48
Organogenesis Inc.2$48
Genentech USA, Inc.3$43
Kowa Pharmaceuticals America, Inc.3$42
Sunovion Pharmaceuticals Inc.3$42
Shield Therapeutics Inc2$41
Xeris Pharmaceuticals, Inc.2$38
Saluda Medical Americas, Inc.1$33
Exact Sciences2$30
Halozyme Inc2$29
Mannkind Corporation2$27
Radius Health, Inc.1$27
Lifescan, Inc.1$26
Nevro Corp.1$25
Cequr Corporation1$24
Optos, Inc.1$24
Vertex1$23
Medtronic1$21
Globus Medical1$21
Axsome Therapeutics, Inc.1$20

How this compares

$13,216 in reported general payments places this provider in the 95th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$120,623
Medicare patients
472
Services billed
2,867

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl22$114,613
OzempicSemaglutide72$103,305
EliquisApixaban88$90,315
FarxigaDapagliflozin Propanediol74$89,550
JardianceEmpagliflozin53$71,918
JanuviaSitagliptin Phosphate50$66,596
XareltoRivaroxaban43$50,075
MounjaroTirzepatide39$45,105
TrulicityDulaglutide28$44,907
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$28,499
EntrestoSacubitril/Valsartan21$25,842
LinzessLinaclotide23$20,735
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$18,370
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$16,121
Sildenafil Citrate18$15,193

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,316$103,30572 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,481$102,79387 claims
PfizerEliquis, Premarin$1,067$95,836100 claims
Lilly USA, LLCMounjaro, Trulicity$750$90,01267 claims
Boehringer IngelheimJardiance, Stiolto Respimat$781$85,37764 claims
MerckJanuvia$270$66,59650 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arexvy, Breo Ellipta$440$60,30789 claims
Johnson & JohnsonXarelto$298$50,07543 claims
AbbVieLinzess, Savella, Synthroid$1,691$34,25896 claims
NovartisEntresto$160$25,84221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →